menu
    • menu

    Company profile for Allarity Therapeutics

    NEW Drugs in Dev: 7
    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    Contact Supplier

    Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

    Virtual Booth

    Contact Supplier

    Arlanda is your partner for the Brazil market.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Allarity Therapeutics is a late clinical-stage, precision medicine company actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Allarity’s clinical program includes six anti-cancer assets in mid- to late-stage clinical development. Our programs and partnerships leverage our proprietary, highly accurate Drug Response Predictor (DRP®) technology to refine patient sel...
    Allarity Therapeutics is a late clinical-stage, precision medicine company actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Allarity’s clinical program includes six anti-cancer assets in mid- to late-stage clinical development. Our programs and partnerships leverage our proprietary, highly accurate Drug Response Predictor (DRP®) technology to refine patient selection and improve clinical outcomes. Our DRP® technology has been broadly validated across an extensive array of therapies & tumor types with a high degree of accuracy for matching the right patient to the right drug.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Allarity TherapeuticsDenmark Flag
    Country
    Country
    Denmark
    Address
    Address
    Venlighedsvej 1 2970 Horsholm
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://allarity.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/allaritytx/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/allaritytx

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    ELCC

    ELCC

    Not Confirmed

    envelop Contact Supplier

    ELCC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Allarity Therapeutics Secures $20M for Stenoparib's FDA Approval
    Allarity Therapeutics Secures $20M for Stenoparib's FDA Approval

    06 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/06/3250989/0/en/Allarity-Therapeutics-Closes-20-Million-Financing-to-Accelerate-the-Advance-of-Stenoparib-Toward-FDA-Approval-and-Commercialization.html

    GLOBENEWSWIRE
    06 Mar 2026
    Share Share
    Allarity Therapeutics Opens Phase 2 Trial With US Veterans
    Allarity Therapeutics Opens Phase 2 Trial With US Veterans

    03 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/03/3230960/0/en/Allarity-Therapeutics-announces-that-its-collaborative-Phase-2-trial-with-the-United-States-Veteran-s-Administration-Combining-Stenoparib-with-Temozolomide-in-Relapsed-Small-Cell-L.html

    GLOBENEWSWIRE
    03 Feb 2026
    Share Share
    Allarity Therapeutics Releases 2025 CEO Letter To Shareholders
    Allarity Therapeutics Releases 2025 CEO Letter To Shareholders

    31 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/31/3211767/0/en/Allarity-Therapeutics-Issues-2025-End-of-Year-CEO-Letter-to-Shareholders.html

    GLOBENEWSWIRE
    31 Dec 2025
    Share Share
    Allarity Therapeutics Unveils Q3 Financials & Business Update
    Allarity Therapeutics Unveils Q3 Financials & Business Update

    14 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/14/3188337/0/en/Allarity-Therapeutics-Provides-Third-Quarter-2025-Financial-Results-and-Provides-Business-Updates.html

    GLOBENEWSWIRE
    14 Nov 2025
    Share Share
    Allarity Therapeutics Unveils Stenoparib/2x-121 Phase 2 Data:
    Allarity Therapeutics Unveils Stenoparib/2x-121 Phase 2 Data:

    22 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/22/3153846/0/en/Allarity-Therapeutics-Presents-New-Phase-2-Clinical-Data-for-Stenoparib-2X-121-Showing-Landmark-Median-Overall-Survival-Has-Now-Surpassed-25-Months.html

    GLOBENEWSWIRE
    22 Sep 2025
    Share Share
    Allarity CEO to Present at Biomarkers & Precision Medicine 2025
    Allarity CEO to Present at Biomarkers & Precision Medicine 2025

    17 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/17/3151554/0/en/Allarity-Therapeutics-CEO-to-Present-at-Biomarkers-Precision-Medicine-2025.html

    GLOBENEWSWIRE
    17 Sep 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search